PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics (PTCT) filed a Form 144 notice for a proposed sale of 55,000 shares of common stock. The filing lists an aggregate market value of $3,632,946.95 for the shares and an approximate sale date of 10/03/2025. The designated broker is Fidelity Brokerage Services LLC, and the shares are listed on NASDAQ.
The shares were acquired via an option grant dated 01/04/2016, from the issuer, with payment noted as cash on 10/03/2025. The filing also reports 79,438,094 shares outstanding. This notice reflects an intention to sell under Rule 144 and does not itself execute a transaction.
PTC Therapeutics filed a Form 144 notice indicating a proposed sale of 12,000 common shares with an aggregate market value of $780,000.00, to be sold approximately on 10/03/2025 on NASDAQ. The shares are reported as acquired in connection with an option granted on 01/04/2016, with the acquisition/transaction dated 10/03/2025, and the payment method noted as cash. The filing also discloses a prior sale by the same account: 1,667 shares sold on 08/28/2025 for $83,601.72. The filer attests there is no undisclosed material adverse information and includes the standard signature/attestation language.
PTC Therapeutics insider transactions by director Emma Reeve show multiple share sales and option exercises on 09/11/2025 under a pre-established Rule 10b5-1 plan. The filing discloses exercises of stock options to acquire 10,000 shares at a $25.69 exercise price and 837 shares at $33.63, both currently exercisable. Concurrently, there are several open-market sales executed at $59.50 per share (including sales of 3,534; 1,334; 10,000; and 837 shares in separate line items). The reporting person adopted the 10b5-1 plan on March 4, 2025. After the reported transactions the filing shows beneficial ownership snapshots, with one line indicating 10,332 shares beneficially owned following certain sales and other lines reflecting different post-transaction totals where option exercises increased holdings.
Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics, Inc. (PTCT), reported multiple share transactions effected under a written Rule 10b5-1 plan adopted December 5, 2024. On September 11 and 12, 2025 he exercised and purchased common stock via stock options priced at $38.10 and simultaneously sold portions of his holdings in a series of transactions with weighted average sale prices ranging from $61.00 to $62.18 per share. Following the reported trades, the filing shows beneficial ownership of 103,901 common shares. The form also discloses outstanding stock options exercisable into specific share amounts with an expiration date of January 6, 2032 and vesting tied to a grant from January 7, 2022.
PTC Therapeutics director David P. Southwell reported option exercise and concurrent sale on 09/09/2025. He exercised 12,000 stock options with an exercise price of $30.86 per share and immediately sold 12,000 shares at a weighted average sale price of $58.34 per share. The filing shows 16,850 shares beneficially owned following the transactions and that the exercised options were currently exercisable. The reporting was made by attorney-in-fact Avraham S. Adler on 09/11/2025. The seller undertakes to provide trade-level details on request to the SEC.
Form 144 notice for PTC Therapeutics, Inc. (PTCT): An individual proposes to sell 22,664 shares of common stock, with an aggregate market value of $1,382,537.32, on or about 09/11/2025 through Fidelity Brokerage Services (NASDAQ). The filing shows the shares were acquired as an option granted on 01/07/2022 and payment is expected in cash upon sale. The issuer has 79,438,094 shares outstanding, and the filing also discloses a recent sale by Mark Boulding of 2,813 shares on 08/15/2025 for gross proceeds of $136,646.45. The filer attests they are not aware of undisclosed material adverse information.
PTC Therapeutics (PTCT) filed a Rule 144 notice reporting a proposed sale of 15,705 common shares through Fidelity Brokerage Services on 09/11/2025 with an aggregate market value of $934,447.50. The filing lists multiple prior acquisitions of the shares primarily from restricted stock vesting in 2023 and 2024 and from option exercises/grants with specified acquisition dates and quantities. The seller represents they are unaware of undisclosed material adverse information and the form indicates no sales by the person in the prior three months.
PTC Therapeutics insider transactions on 09/08/2025: Eric Pauwels, the company's Chief Business Officer and a director, executed a series of option exercises and contemporaneous sales under a Rule 10b5-1 plan adopted June 4, 2025. The filings show multiple option exercises at strike prices between $11.23 and $30.86 that resulted in acquisitions totaling 59,060 shares across several tranches. Simultaneously, Pauwels sold a total of 59,060 shares in multiple trades at weighted average sale prices in the mid-$56 range, reducing his reported beneficial ownership to 72,912 shares. Certain acquired shares include 272 shares from the employee stock purchase plan.
PTC Therapeutics, Inc. (PTCT) filed a Form 144 notice for a proposed sale of 12,000 common shares held at Fidelity Brokerage Services. The filing shows an aggregate market value of $700,128.81 and reports 79,438,094 shares outstanding, with an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired via an option granted on 01/04/2016 and are to be sold for cash; no sales in the prior three months were reported.
PTC Therapeutics Form 144 filing notifies a proposed sale of 39,850 common shares through Fidelity Brokerage Services with an aggregate market value of $2,268,373.83, intended for sale on 09/08/2025 on NASDAQ. The filing lists four lots acquired via stock options granted in 2016, 2017 and 2018 and shows cash payment on the stated sale date. The filing states there were no securities sold by the reporting person in the prior three months and includes the required attestation that the seller does not possess undisclosed material information. The notice follows Rule 144 disclosure requirements.